YOLFTbeta
BlossomHill Therapeutics, Inc. Common Stock

BlossomHill Therapeutics, Inc. Common Stock

BLSM · NASDAQ · Healthcare / Biotechnology

14.02USD-0.82 (-5.53%)

Price History

Full chart

Market Stats

Previous Close14.84
Open15.23
Day Range13.40 – 15.68
52-Week Range15.25 – 27.99
Volume222.59K
Market Cap650.64M
P/E (TTM)0.00
Forward P/E0.00
EPS-2.42
Dividend Yield0.00%
50-Day Avg19.80
200-Day Avg19.80

About

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Jingrong Jean Cui Ph.D.
  • Employees63
  • Headquarters10255 Science Center Drive, San Diego, CA, United States, 92121, USA
  • Websitehttps://bhtherapeutics.com

Leadership

  • Dr. Yishan Li M.B.A., Ph.D.Co-Founder & Executive Chairman · b. 1965
  • Dr. Jingrong Jean Cui Ph.D.Scientific Founder, President, CEO & Director · b. 1963
  • Mr. Jason A. Keyes M.B.A.CFO & Executive VP · b. 1971
  • Dr. Geoff Oxnard M.D.Chief Medical Officer & Executive VP · b. 1977
  • Dr. Vincent Liptak J.D., M.B.A., Ph.D.General Counsel & Executive VP · b. 1971
  • Dr. Zachary F. Zimmerman M.D., Ph.D.Senior Vice President of Clinical Development
  • Dr. Eugene Y. Rui Ph.D.Senior Vice President of Chemistry
  • Dr. Z. Jesse Shao Ph.D., R.Ph.Senior Vice President of CMC
  • Dr. Ashley Preston Ph.D.Senior VP and Head of Regulatory Affairs & Quality Assurance
  • Dr. Antonio Garrido-Montalban Ph.D.Senior Vice President of Drug Substance

Financials

Income Statement

Currency: USD2024-12-312025-12-31
Total Revenue00
Operating Income-36.40M-64.02M
EBITDA-36.05M-63.58M
Net Income-30.70M-60.55M
R&D31.81M56.14M

Balance Sheet

Currency: USD2024-12-312025-12-31
Total Assets106.78M162.97M
Total Liabilities179.66M294.70M
Total Equity-72.88M-131.73M
Cash100.15M136.68M
Total Debt525.00K22.40M
Net Debt-99.62M-114.28M

Cash Flow

Currency: USD2024-12-312025-12-31
Operating Cash Flow-31.42M-46.92M
Investing Cash Flow-92.00K-1.07M
Financing Cash Flow17.56M84.53M
Capital Expenditure92.00K1.07M
Free Cash Flow-31.51M-47.99M
FCF to OCF100.29%102.27%

Earnings

Report DateSep 18, 2026
EPS Estimate-0.84
EPS Actual-8.75
Surprise-941.67%
TimingPre-market

Key Statistics & Ratios

Market Cap650.64M
Enterprise Value638.07M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book0.00
EPS-2.42
Book Value-63.15
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-84.74M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity0.00%
Return on Assets0.00%
Shares Outstanding31.78M
Shares Float17.22M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%